ArticleWorld journal of oncology2026
The Association Between Potential Nuclear Factor-Kappa B1 Gene Polymorphism rs28362491 and miR-206 Level in Patients With Acute Lymphoblastic Leukemia.
Article in World journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: microRNAs (miRNAs) and the nuclear factor-kappa B1 (NF-κB1) signaling pathway play a critical role in leukemogenesis. The miR-206 and NF-κB1-94 ATTG polymorphism (rs28362491) have a potential impact on cancer progression and treatment response. The primary objective of this study was to evaluate the levels of expression of miR-206, the genotypic distribution of the NF-κB1-94 ATTG polymorphism, and the secondary objective was to assess their relationship in patients with acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL), and healthy controls. Methods: This was a retrospective case-control study conducted at King Hussein Cancer Center, from April to July 2023 and involved three distinct groups, ALL (n = 46), HL (n = 35), and healthy individuals (n = 30). Tissue samples were collected from patients, while blood samples from the control group. Data were retrieved from electronic medical records. The samples were analyzed for miR-206 expression and NF-κB1-94 ATTG polymorphism genotypes. miR-206 levels were measured using quantitative real-time polymerase chain reaction (qRT-PCR). Genotypic distributions were determined through PCR and subsequent sequencing. Statistical analyses evaluated correlations between miR-206 levels, NF-κB1 genotypes, and clinical outcomes. Results: miR-206 expression was significantly lower in ALL patients compared to healthy controls (P < 0.0001), with mean values of 0.01 ± 0.1 in ALL, 0.01 ± 0.02 in HL, and 2,777.2 ± 31.55 in control subjects, suggesting a potential tumor suppressor role in ALL and HL. The genotypic distribution of the NF-κB1 (rs28362491) polymorphism revealed that homozygous Ins/Ins genotype was most prevalent in ALL compared with controls (41.3% vs 12%, P = 0.0048), and lowest in HL (28.5%). The heterozygous Ins/Del genotype was most prevalent in controls (60%), HL (42.8%), and least common in ALL (30.4%), indicating a possible protective effect against ALL. Further analysis showed no significant differences in miR-206 levels across the NF-κB1 genotypes (P = 0.9086) according to remission status for heterozygous Ins/Del and homozygous Del/Del compared to homozygous Ins/Ins. Conclusions: This study suggests that: 1) there was no significant difference in miR-206 expression across different NF-κB1-94 ATTG polymorphism genotypes; 2) reduced miR-206 expression could have a potential tumor suppressor role in ALL patients; 3) there was no significant genotype effect on remission status in ALL patients; and 4) both abnormalities could serve as biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.